November 05, 2025
SAN ANTONIO, Jan. 30, 2025 – A UT Health San Antonio School of Dentistry researcher and her pioneering biotechnology company partnered with the school to earn a prestigious $400,000 Small Business Technology Transfer (STTR) grant from the National Institutes of Health to speed development of a breakthrough oral cancer drug.
Cara Gonzales, DDS, PhD, assistant professor in the Department of Comprehensive Dentistry at UT Health San Antonio, and founder of San Antonio-based Keraceuticals, will investigate CIDD99, a first-in-class drug targeting a novel anti-cancer pathway, promising an effective option for combating aggressive cancer types with fewer adverse side effects.
